^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

miR-34a expression

i
Other names: MIR34A, mir-34, MIRN34A, mir-34a, miRNA34A
Entrez ID:
Related biomarkers:
23d
Lower expressions of MIR34A and MIR31 in colo-rectal cancer are associated with an enriched immune microenvironment. (PubMed, Pathol Res Pract)
Lower MIR34A and MIR31 levels are associated with higher TILs density in CRC. Unlike other cancers where MIR34A has anti-tumour effects, there was no statistically significant correlation between its expression and the pT or TNM stages in this study. Increased TILs being a good prognostic indicator, this suggests MIR34A and MIR31 may help CRC cells evade immune surveillance. Aberrant p53 expression downregulates MIR34A, underscoring the therapeutic potential of miRs.
Journal
|
TP53 (Tumor protein P53) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MIR21 (MicroRNA 21) • MIR34A (MicroRNA 34a-5p) • MIR31 (MicroRNA 31)
|
TP53 expression • CTNNB1 expression • miR-34a expression • miR-34a underexpression
1m
MicroRNA-34a negatively regulates Netrin1 and mediates MEK/ERK pathway to regulate chemosensitivity of gastric cancer cells. (PubMed, Discov Oncol)
miR-34a targets and negatively regulates Netrin1 to mediate the proliferation, apoptosis, apoptosis, migration, and invasion of drug-resistant gastric cancer cells via the MEK/ERK pathway, and change the chemosensitivity in GC cells. miR-34a/Netrin1/MEK/ERK axis may serve as a novel therapeutic target for chemoresistance in GC, it is of great significance for overcoming drug resistance and developing new therapeutic strategies for GC.
Journal
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1) • CDH1 (Cadherin 1) • MIR34A (MicroRNA 34a-5p) • MMP9 (Matrix metallopeptidase 9) • PCNA (Proliferating cell nuclear antigen) • NTN1 (Netrin 1)
|
CDH1 expression • MAPK1 overexpression • miR-34a expression
|
cisplatin
2ms
Regulatory role and molecular mechanism of METTL14 in vascular endothelial cell injury in preeclampsia. (PubMed, Biomol Biomed)
Overexpression of miR-34a-5p or silencing of FOXP1 reversed the protective effects of METTL14 silencing on cell injury in the PE model. In conclusion, METTL14 mediated m6A modification to promote miR-34a-5p expression, leading to the inhibition of FOXP1 expression, which aggravated endothelial cell damage in the PE cell model.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • ICAM1 (Intercellular adhesion molecule 1) • MIR34A (MicroRNA 34a-5p) • FOXP1 (Forkhead Box P1) • VCAM1 (Vascular Cell Adhesion Molecule 1) • METTL14 (Methyltransferase 14)
|
miR-34a expression • miR-34a overexpression • miR-34a underexpression
6ms
Blocking lncRNA HCG18 re-sensitizes Taxol resistant lung cancer cells to Taxol through modulating the miR-34a-5p/HDAC1 axis. (PubMed, J Chemother)
In conclusion, our in vitro and in vivo results uncover a novel molecular mechanism by which HCG18 promotes Taxol resistance through modulation of the miR-34a-5p/HDAC1 axis. These findings contribute to the diagnosis and treatment of chemo-resistant lung cancer.
Journal
|
MIR34A (MicroRNA 34a-5p) • HDAC1 (Histone Deacetylase 1)
|
miR-34a expression
|
paclitaxel
7ms
Bioinformatics study and experimental evaluation of miR-182, and miR-34 expression profiles in Tuberculosis and lung cancer. (PubMed, Tuberc Respir Dis (Seoul))
Reducing the expression pattern of these microRNAs indicates their role in lung cancer and tuberculosis occurrence. Therefore, these microRNAs can be used as a biomarker for prognosis, diagnosis, and treatment methods.
Journal
|
MIR34A (MicroRNA 34a-5p) • MIR182 (MicroRNA 182)
|
miR-34a expression
8ms
Liquid biopsy utilizing miRNA in patients with advanced breast cancer treated with cyclin‑dependent kinase 4/6 inhibitors. (PubMed, Oncol Lett)
Plasma-based expression of miR-21, -34a, -193b, -200a and -200b effectively distinguished patients with ABC who responded to CDK4/6i treatment from patients who were resistant. However, longitudinal studies are required to verify the predictive and prognostic potential of miRNA.
Journal • Liquid biopsy • Metastases • Biopsy
|
HER-2 (Human epidermal growth factor receptor 2) • MIR200B (MicroRNA 200b) • MIR21 (MicroRNA 21) • MIR34A (MicroRNA 34a-5p) • MIR193B (MicroRNA 193b) • MIR200A (MicroRNA 200a)
|
miR-34a expression
9ms
An In Vitro Study for the Role of Schizophrenia-Related Potential miRNAs in the Regulation of COMT Gene. (PubMed, Mol Neurobiol)
RNA-IP data have shown that the amount of COMT pulled down by Ago2 was increased after miR-30a-5p and miR-34a-5p transfections. RNA-IP results revealed that miR-30a-5p and miR-34a-5p are direct targets for the COMT gene.
Preclinical • Journal
|
MIR34A (MicroRNA 34a-5p) • MIR30A (MicroRNA 30a) • MIR30E (MicroRNA 30e) • COMT (Catechol-O-Methyltransferase)
|
miR-34a expression
9ms
Impact of Long-Lasting Environmental Factors on Regulation Mediated by the miR-34 Family. (PubMed, Biomedicines)
Moreover, the apoptogenic capacity of miR-34 induced via phthalate administration in the testes has been shown to negatively influence germ cell proliferation. To conclude, as the oncostatic and positive neuromodulatory functions of the miR-34 family can be strongly influenced by environmental factors, their interactions should be taken into consideration in translational medicine.
Review • Journal
|
CCND1 (Cyclin D1) • MIR34A (MicroRNA 34a-5p) • CRY1, Cryptochrome Circadian Regulator 1, • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
CCND1 expression • CRY1 mutation • miR-34a expression
9ms
Bone marrow microRNA-34a is a good indicator for response to treatment in acute myeloid leukemia. (PubMed, Oncol Res)
miR-34a could be a beneficial diagnostic biomarker for AML patients. In addition, it serves as a good indicator for response to therapy, which could possibly identify patients who are refractory to treatment with 100% sensitivity and 75% specificity.
Journal
|
MIR34A (MicroRNA 34a-5p)
|
miR-34a expression
10ms
Acacetin inhibited non-small-cell lung cancer (NSCLC) cell growth via upregulating miR-34a in vitro and in vivo. (PubMed, Sci Rep)
In vivo, intratumor injection of miR-34a antagomir could drastically suppress the anti-tumor formation effects of acacetin in A549-xenografted nude mice. Overall, our results showed that acacetin inhibits cell proliferation and induces cell apoptosis of NSCLC cells by regulating miR-34a.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • MIR34A (MicroRNA 34a-5p) • CCNB1 (Cyclin B1)
|
PD-L1 expression • TP53 expression • miR-34a expression
10ms
MiR-34a functions as a tumor suppressor in oral cancer through the inhibition of the Axl/Akt/GSK-3β pathway. (PubMed, J Dent Sci)
Our findings highlight the significance of the miR-34a/Axl/Akt/GSK-3β signaling axis in modulating the malignancy of oral cancer cells. Targeting miR-34a may hold therapeutic potential in oral cancer treatment, as manipulating its expression can attenuate the aggressive behavior of oral cancer cells via the Axl/Akt/GSK-3β pathway.
Journal
|
AXL (AXL Receptor Tyrosine Kinase) • MIR34A (MicroRNA 34a-5p)
|
AXL overexpression • miR-34a expression • miR-34a overexpression • miR-34a underexpression
11ms
HDAC6-MYCN-CXCL3 axis mediates allergic inflammation and is necessary for allergic inflammation-promoted cellular interactions. (PubMed, Mol Immunol)
Recombinant CXCL3 protein also increased the expression of markers of M2 macrophage. Thus, the identification of the novel role of HDAC6-MYCN-CXCL3 axis can help better understand the pathogenesis of anaphylaxis.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • MIR34A (MicroRNA 34a-5p) • HDAC6 (Histone Deacetylase 6) • CXCL3 (C-X-C Motif Chemokine Ligand 3)
|
MYC expression • HDAC6 expression • miR-34a expression
1year
Silencing METTL14 alleviates liver injury in non-alcoholic fatty liver disease by regulating mitochondrial homeostasis. (PubMed, Biomol Biomed)
The overexpression of miR-34a-5p or inhibition of SIDT2 expression negated the alleviative effects of METTL14 silencing on mitochondrial homeostasis imbalance. In conclusion, METTL14, through m6A modification, modulates the miR-34a-5p/SIDT2 axis, impairing mitochondrial homeostasis in NAFLD.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • MIR34A (MicroRNA 34a-5p) • IL1B (Interleukin 1, beta) • METTL14 (Methyltransferase 14) • MFN2 (Mitofusin 2)
|
miR-34a expression • miR-34a overexpression • miR-34a underexpression
over1year
2-methoxyestradiol restrains non-small cell lung cancer tumorigenesis through regulating circ_0010235/miR-34a-5p/NFAT5 axis. (PubMed, Thorac Cancer)
These findings demonstrated that 2-MeOE2 retarded NSCLC progression by modulating the circ_0010235/miR-34a-5p/NFAT5 axis, thus providing a new perspective for 2-MeOE2 treatment in NSCLC.
Journal
|
MIR34A (MicroRNA 34a-5p) • NFATC1 (Nuclear Factor Of Activated T Cells 1)
|
miR-34a expression
|
Panzem (2-methoxyestradiol)
over1year
miR-21 and miR-34a as biomarkers of radiotherapy skin adverse events in ductal carcinoma in situ (ESMO 2023)
Conclusions Our results suggest that miR-21 and miR-34a expression increases after RT and miR-34a expression might serve as a biomarker of RT skin adverse events. Research grants: ARRS J3-1753, ARRS J3-2527, P1-0170 and P3-0321.
Adverse events
|
MIR21 (MicroRNA 21) • MIR34A (MicroRNA 34a-5p)
|
miR-34a expression
over1year
circFANCA accelerates the malignant process of OSCC by modulating miR-34a/PA28γ signaling. (PubMed, Biochem Biophys Res Commun)
The circFANCA/miR-34a/PA28γ axis facilitates the metastasis of OSCC, and circFANCA and miR-34a have potential to serve as prognostic markers for OSCC patients.
Journal
|
MIR34A (MicroRNA 34a-5p)
|
miR-34a expression
over1year
Investigating the role of miRNA-34a in the resistance of esophageal adenocarcinoma to neoadjuvant chemoradiation therapy (AACR 2023)
Decreased miR-34a expression is associated with radioresistance across a panel of in vitro EAC models and in pre-treatment tumor biopsies from EAC patients having a poor pathological response to neo-CRT. This highlights a potential role for miR-34a as a novel biomarker predicting response to neo-CRT in EAC. Analysis of validated and predicted gene targets of miR-34a identified a number of pathways associated with treatment resistance.
Clinical
|
MIR34A (MicroRNA 34a-5p)
|
miR-34a expression
over1year
miR-34a/DRP-1-mediated mitophagy participated in cisplatin-induced ototoxicity via increasing oxidative stress. (PubMed, BMC Pharmacol Toxicol)
MiR-34a/DRP-1-mediated mitophagy was related to cisplatin-induced ototoxicity and might be a novel target for investigating the treatment and protection of cisplatin-induced ototoxicity.
Journal
|
MIR34A (MicroRNA 34a-5p)
|
miR-34a expression
|
cisplatin
over1year
miR-34a and IRE1A/XBP-1(S) Form a Double-Negative Feedback Loop to Regulate Hypoxia-Induced EMT, Metastasis, Chemo-Resistance and Autophagy. (PubMed, Cancers (Basel))
The HIF1A/IRE1A/XBP-1(S)/p53/miR-34a feedback loop described here represents a central regulator of the response to hypoxia and ER stress that maintains cellular homeostasis. In tumors, the inactivation of p53 and miR-34a may result in IRE1A/XPB-1(S)-mediated EMT and autophagy, which ultimately promotes metastasis and chemoresistance.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • MIR34A (MicroRNA 34a-5p)
|
TP53 expression • HIF1A expression • miR-34a expression
|
5-fluorouracil
almost2years
MYC Causes Multiple Myeloma Progression via Attenuating TP53-Induced MicroRNA-34 Expression. (PubMed, Genes (Basel))
Using the nutlin-3 or Tet-on systems, we caused wild-type (WT) p53 protein accumulation in human MM cell lines (HMCLs) and observed upregulated miR-34 expression...Our results suggest that MYC participates in the suppression of p53-dependent miRNA expressions. Because miRNA expression suppresses tumors, its inhibition leads to MM development and malignant transformation.
Journal
|
TP53 (Tumor protein P53) • MIR34A (MicroRNA 34a-5p)
|
TP53 wild-type • MYC expression • TP53 expression • MYC negative • miR-34a expression
|
Nutlin-3
almost2years
HPV 16 E6 promotes growth and metastasis of esophageal squamous cell carcinoma cells in vitro. (PubMed, Mol Biol Rep)
Our results not only provide evidence that HPV16 E6 promotes cell proliferation, migration, and invasion in ESCC, but also suggests a correlation between HPV infection and E6AP, p53 and miR-34a expression. Consequently, HPV16 E6 may play an important role in ESCC development.
Preclinical • Journal
|
TP53 (Tumor protein P53) • BAX (BCL2-associated X protein) • MIR34A (MicroRNA 34a-5p)
|
TP53 expression • BAX expression • miR-34a expression
almost2years
Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47. (PubMed, J Clin Invest)
Therapeutically, disruption of the KRAS-CD47 signaling axis with KRAS siRNA, the KRASG12C inhibitor AMG 510 or miR-34a mimic suppressed CD47 expression, enhanced the phagocytic capacity of macrophages and restored innate immune surveillance. Our results revealed a direct mechanistic link between active KRAS and innate immune evasion and identified CD47 as a major effector underlying KRAS-mediated immunosuppressive tumor microenvironment.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • CD47 (CD47 Molecule) • MIR34A (MicroRNA 34a-5p)
|
KRAS mutation • CD47 expression • miR-34a expression
|
Lumakras (sotorasib)
2years
Plasma-Based microRNA Expression Analysis in Advanced Stage NSCLC Patients Treated with Nivolumab. (PubMed, Cancers (Basel))
Low miR-34a expression independently predicted for shorter OS (HR: 3.189, 95% CI: 1.193-8.527; p = 0.021) in the non-SqCC subgroup. Our findings suggest that alterations in circulating miR-200c and miR-34a expression levels are associated with the response and outcome in patients with advanced NSCLC treated with anti-PD1 immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
MIR155 (MicroRNA 155) • MIR200B (MicroRNA 200b) • MIR200C (MicroRNA 200c) • MIR34A (MicroRNA 34a-5p)
|
miR-200-c expression • miR-34a expression
|
Opdivo (nivolumab)
2years
MicroRNA34a is associated with chemotherapy resistance, metastasis, recurrence, survival, and prognosis in patient with osteosarcoma. (PubMed, Medicine (Baltimore))
The expression level of serum miR-34a in patients with OS is closely related to the chemotherapy resistance, metastasis, recurrence, and survival of osteosarcoma, which can be used as one of the potential biomarkers and prognosis for the treatment of OS patients. Therefore, miR-34a may be a potential molecular for prediction of the efficacy of chemotherapy and prognosis in OS patients.
Journal
|
MIR34A (MicroRNA 34a-5p)
|
miR-34a expression
2years
Effect Evaluation of Bronchial Artery Embolization for Hemoptysis of Lung Cancer and Changes in Serum Tumor Markers and miR-34 Levels. (PubMed, Contrast Media Mol Imaging)
The efficacy, overall survival (OS) rate, coagulation function, hemoptysis volume, serum tumor markers, and miR-34 expression are compared among all groups at different time points. The experimental results show that the BAE treatment can promote the expression of miR-34 and inhibit the expression of tumor markers, so it can improve the efficacy of patients with lung cancer hemoptysis, improve the symptoms of hemoptysis and coagulation function, and prolong the life cycle of patients.
Clinical • Retrospective data • Journal
|
MIR34A (MicroRNA 34a-5p)
|
miR-34a expression
over2years
LncRNA MNX1-AS1 contributes to lung adenocarcinoma progression by targeting the miR-34a/SIRT1 axis. (PubMed, Am J Transl Res)
Up-regulation of SIRT1 salvaged the effect of silencing MNX1-AS1 on A549 and H1299 cells, to some extent. These results showed that MNX1-AS1 contributes to LAC progression by targeting the miR-34a/SIRT1 axis.
Journal
|
MIR34A (MicroRNA 34a-5p)
|
miR-34a expression
over2years
miR-34a induces neutrophil apoptosis by regulating Cdc42-WASP-Arp2/3 pathway-mediated F-actin remodeling and ROS production. (PubMed, Redox Rep)
Luciferase reporter assay indicated that DOCK8 was a direct target gene of miR-34a. These data indicates miR-34a may induce neutrophil apoptosis by regulating Cdc42-WASP-Arp2/3 pathway-mediated F-actin remodeling and ROS production.
Journal
|
MIR34A (MicroRNA 34a-5p) • CDC42 (Cell Division Cycle 42) • DOCK8 (Dedicator Of Cytokinesis 8)
|
miR-34a expression • miR-34a overexpression
over2years
Autophagy blockade potentiates cancer-associated immunosuppression through programmed death ligand-1 upregulation in bladder cancer. (PubMed, J Cell Physiol)
The autophagy inhibitors chloroquine (CQ) and bafilomycin A1 (Baf-A1) increased PD-L1 expression in BC cells through the ERK-JNK-c-Jun signal-transduction pathway...Our results provide evidence that autophagy blockade and its regulatory pathway affect cancer-associated immunosuppression through PD-L1 elevation. Thus, the coadministration of autophagy inhibitors and a PD-L1 immune checkpoint blockade provides a potential therapeutic approach for treating BC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • MIR34A (MicroRNA 34a-5p)
|
PD-L1 expression • PD-L1 elevation • miR-34a expression • miR-34a overexpression
|
chloroquine phosphate
over2years
hsa-miR-34a-5p Ameliorates Hepatic Ischemia/Reperfusion Injury Via Targeting HNF4α. (PubMed, Turk J Gastroenterol)
miR-34a-5p possibly protected the liver from I/R injury through downregulating Hepatocyte nuclear factor 4α to inhibit the JNK/P38 signaling pathway.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MIR34A (MicroRNA 34a-5p) • MAPK8 (Mitogen-activated protein kinase 8)
|
miR-34a expression • miR-34a-5p underexpression
over2years
miR-34a predicts the prognosis of advanced-stage external auditory canal squamous cell carcinoma. (PubMed, Acta Otolaryngol)
We demonstrated that the expression level of miR-34a was higher in early-stage EACSCC and lower in advanced-stage EACSCC. The expression level of miR-34a may predict a prognosis in patients with advanced-stage EACSCC.
Journal
|
MIR34A (MicroRNA 34a-5p)
|
miR-34a expression
over2years
Long non-coding RNA MEG3 regulates the progress of osteoarthritis by regulating the miR-34a/Klotho axis. (PubMed, Ann Transl Med)
Meanwhile, lncRNA MEG3 overexpression upregulated the expression of miR-34a, Bax, TGF-β1, Caspase3 and Caspase8, and downregulated the expression of Klotho, FGF23 and Bcl-2. lncRNA MEG3 regulated the expression of FGF23, Bcl-2, Bax, TGF-β1, Caspase 3, and Caspase 8 by regulating the miR-34a/Klotho axis, thereby affecting the progress of OA.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • MIR34A (MicroRNA 34a-5p) • CASP8 (Caspase 8) • TGFB1 (Transforming Growth Factor Beta 1) • KL (Klotho)
|
BCL2 expression • BAX expression • miR-34a expression
over2years
miR-34a-5p plays an inhibitory role in hepatocellular carcinoma by regulating target gene VEGFA. (PubMed, Malays J Pathol)
These results suggest that miR-34a-5p could inhibit the occurrence and development of HCC by targeting VEGFA.
Journal
|
MIR34A (MicroRNA 34a-5p)
|
VEGFA expression • miR-34a expression
over2years
KCNQ1OT1 polymorphism rs35622507 and methylation status of KCNQ1OT1 promoter influences the drug resistance to L-OHP. (PubMed, Aging (Albany NY))
The drug resistance in the treatment of colon cancer is most reduced in patients carrying allele 10 and methylated in KCNQ1OT1 promoter. This function is accomplished by the signaling pathway of KCNQ1OT1/miR-34a/ATG4B.
Journal
|
MIR34A (MicroRNA 34a-5p) • KCNQ1OT1 (KCNQ1 Opposite Strand/Antisense Transcript 1) • ATG4B (Autophagy Related 4B Cysteine Peptidase)
|
miR-34a expression
|
oxaliplatin
over2years
Non-invasive diagnostic potential of microRNA-203 in liquid biopsy of urothelial carcinoma of bladder. (PubMed, Mol Cell Biochem)
Higher miR-203 levels in the urine of Indian UBC patients demonstrate its non-invasive diagnostic ability out of the three miRNAs studied. Our results characterize the non-invasive diagnostic potential of CD44-linked miR-203 in the urine of Indian UBC patients, which could be utilized in clinical settings in future after validation in larger patient cohort.
Journal • Liquid biopsy
|
CD44 (CD44 Molecule) • MIR34A (MicroRNA 34a-5p) • MIR203A (MicroRNA 203a)
|
CD44 expression • miR-34a expression
over2years
Polysaccharide of Atractylodis Macrocephalae Rhizoma inhibits expression of immune checkpoint PD-L1 by targeting miR-34a in esophageal carcinoma cells (PubMed, Zhongguo Zhong Yao Za Zhi)
Thus, the PAMR may inhibit PD-L1 by increasing the expression of miR-34 a and regulating its downstream target genes. In conclusion, PAMR inhibits the expression of PD-L1 mainly by inducing miR-34 a.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • MIR34A (MicroRNA 34a-5p)
|
PD-L1 overexpression • miR-34a expression
over2years
WNT signaling modulates chemoresistance to temozolomide in p53-mutant glioblastoma multiforme. (PubMed, Apoptosis)
Combined treatment of TMZ with WNT inhibitor or miR34a mimic induced drug sensitivity of p53-mutant GBM cells and extended survival in xenograft mice in vivo. Our findings provide insight into understanding the molecular mechanism of GBM chemoresistance to TMZ and facilitating to develop novel treatment strategy to combat p53-mutant GBM by targeting miR-34a/WNT6 axis.
Journal
|
TP53 (Tumor protein P53) • MIR34A (MicroRNA 34a-5p)
|
TP53 mutation • miR-34a expression
|
temozolomide
over2years
Crocin induces ROS-mediated papillary thyroid cancer cell apoptosis by modulating the miR-34a-5p/PTPN4 axis in vitro. (PubMed, Toxicol Appl Pharmacol)
Crocin promoted apoptosis and increased caspase-3 activity and LDH release, which were reversed by ROS scavenger N-acetyl-L-cysteine (NAC), miR-34a overexpression, and PTPN4 silencing. To conclude, crocin promoted ROS-mediated apoptosis of PTC cells by modulating the miR-34a-5p/PTPN4 axis.
Preclinical • Journal
|
CASP3 (Caspase 3) • MIR34A (MicroRNA 34a-5p)
|
miR-34a expression • miR-34a overexpression
almost3years
The miR-34a/WNT7B modulates the sensitivity of cholangiocarcinoma cells to p53-mediated photodynamic therapy toxicity. (PubMed, Biochem Biophys Res Commun)
Under PDT treatment, WNT7B knockdown inhibited the Wnt signaling and cell viability, and promoted cell apoptosis, while miR-34a-5p suppression showed the opposite trends; WNT7B knockdown partially attenuated miR-34a-5p inhibition effects on PDT-treated cholangiocarcinoma cells. In conclusion, PDT treatment induces p53-induced miR-34a transactivation to inhibit cholangiocarcinoma cell proliferation; the miR-34a-5p/WNT7B axis and Wnt signaling are involved.
Journal
|
MIR34A (MicroRNA 34a-5p) • WNT7B (Wnt Family Member 7B)
|
TP53 expression • miR-34a expression
almost3years
HCV Interplay With Mir34a: Implications in Hepatocellular Carcinoma. (PubMed, Front Oncol)
Since miR34 expression was increased in Huh7.5 EVs, we hypothesized a paracrine mechanism of viral infection mediated by miR34a cargo of EVs. The balance between viral infection and cell transformation may raise some questions on the possible use of antiviral drugs in association with antineoplastic treatment.
Journal
|
MIR34A (MicroRNA 34a-5p)
|
miR-34a expression
almost3years
XIST/miR-34a-5p/PDL1 axis regulated the development of lung cancer cells and the immune function of CD8 T cells. (PubMed, J Recept Signal Transduct Res)
In the co-culture system, XIST targeted miR-34a-5p to inhibit cytokines secretion and promote the expression of immunosuppressive molecules. XIST/miR-34a-5p/PDL1 axis was involved in the malignant biological behavior of lung cancer cells and the immune function of CD8 T cells.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • MIR34A (MicroRNA 34a-5p) • XIST (X Inactive Specific Transcript)
|
PD-L1 expression • miR-34a expression